Upfront vs Milestone: What a $3.2B Licensing Deal Actually Pays

In a pharmaceutical licensing announcement, only one line item is money that is certain the day the contract is signed: the upfront payment. Alteogen's ALT-B4 licence agreement with Novartis, signed on 2 September 2026, carries a headline value of up to $3.223 billion (about 4.4165 trillion won) according to Money Today TheBio — but that figure is a ceiling that assumes every option is exercised and every development and commercial milestone is met. In a survey of 19 Korean companies' licensing deals by BioSpectator, upfront payments accounted for just 0.48% to 5.8% of headline value. Reading the gap between the headline and the cash is the first skill these announcements demand.

The money arrives in four separate moments

The consideration in a licence deal is a sum of items with very different characters. The upfront is paid at signing and is generally non-refundable. Option exercise fees appear only if the partner decides to apply the technology to a particular indication or product. Development milestones are tied to passing preclinical work and Phase 1, 2 and 3 trials; regulatory and sales milestones are tied to agency approval and revenue thresholds. Royalties accrue continuously on net sales once a product is commercialised.

The Alteogen deal follows this shape. The $3.223 billion total combines the signing fee, option exercise fees and milestones; royalties on net sales sit outside that number as a separate stream. Detailed terms were withheld under confidentiality obligations, which means the upfront amount itself is not public.

Two deals with identical headline numbers can differ completely in when the cash lands and how likely it is to land at all. The headline is a sum with no probabilities applied; the upfront is the portion whose probability is already one.

Applying observed upfront ratios to a $3.2B headline

Since Alteogen's upfront is undisclosed, applying the disclosed ratios from other deals to this headline shows how wide the range is. The table multiplies $3.223 billion by each case's ratio. Won figures use roughly 1,370 won per dollar, back-solved from the disclosed conversion (4.4165 trillion won divided by $3.223 billion).

The same 4.4 trillion won deal could mean 70.7 billion won in hand or 3.62 trillion won. Applying the observed Korean distribution of 0.48-5.8% puts most domestic deals in the top two rows. The remaining four trillion won arrives only as conditions are met over several years, and never arrives at all if a trial fails or development stops.

What a high upfront ratio actually signals

The upfront ratio measures how much risk the partner accepted today. BioSpectator frames it directly: the higher the upfront share, the more risk the counterparty has taken on. The same logic runs backwards — Vertex paying a $900 million upfront for CTX001 implies a valuation of the asset above $9 billion.

The ratio correlates with development stage. As DailyPharm documents, late-stage and approved assets command high upfront shares while preclinical assets sit in the 1-2% band. The distance between 82% and 1.6% in the table above is largely the distance between those stages.

Judging deal quality by ratio alone misfires in three ways. First, platform and enabling-technology deals stack options across multiple products into the headline, inflating the denominator and depressing the ratio — a subcutaneous formulation technology applied to several products, like ALT-B4, falls in this category. Second, when royalties sit outside the headline, the entire post-launch cash flow is excluded from the ratio. Third, if the upfront is paid in instalments or carries clawback conditions, the premise that it is non-refundable weakens. The ratio is a starting point, not a verdict.

A headline contract value is a sum of best-case outcomes; the upfront is the size of the conviction the partner paid for today.

Four lines to look for in disclosures after July 2026

Korea's Financial Supervisory Service moved against the headline-only convention. According to Money Today, a guideline issued in July 2026 requires licensing disclosures to break the consideration into upfront, development milestones, regulatory and sales milestones, and royalties. The stated rationale: publishing only the headline made deals read as larger than the cash actually received, and contingent items were being mistaken for amounts fixed at signing. The regulator said it will check compliance when reviewing securities registration statements filed for IPOs and demand corrections.

In practice, look for four lines in the filing: the upfront amount, total development milestones, total regulatory and sales milestones, and whether the royalty rate is disclosed. If those four are separated, you can do the division yourself. If there is still only a single headline number, the deal was written the old way.

How slowly a signed contract converts into recognised revenue is a separate question with the same structure — see the calculation of how fast an order backlog turns into revenue. A contract is signed once, but the income statement receives it in pieces, at each moment a condition is satisfied.

What to watch

• The absolute upfront amount alongside its share of the headline — never the ratio alone
• Whether it is a single-asset deal or a platform deal stacking multi-product options into the total
• How milestones split between development stages and regulatory/sales triggers
• Whether the royalty rate is inside the headline or separate from it
• Clawback and termination clauses, and whether the upfront is paid in instalments
• Where the upfront lands in the next quarterly statements — revenue or contract liability

Sources

• Alteogen signs ALT-B4 licence with Novartis, up to 4.4 trillion won (Money Today TheBio)
• What does the upfront payment mean in a licensing deal? (BioSpectator)
• Trillion-won licensing headlines no longer fly: biotech disclosure overhaul (Money Today)
• Licensed-out drugs: the correlation between development stage and upfront share (DailyPharm)